Global Angiofibroma Drugs Market, By Treatment (Excision, Dermabrasion, Beta Blockers Medication, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
Angiofibroma Drugs Market Analysis and Size
The angiofibroma drugs market is projected to witness significant growth during the forecast period. Angiofibromas are caused by a local overgrowth of fibroblasts, collagen, and blood vessels. In tuberous sclerosis, mutations exist in tuberous sclerosis complex 1 (TSC1), encodes the protein hamartin, and tuberous sclerosis complex 2 (TSC2), which encodes the protein tuberin. The most common treatment for angiofibroma is surgery. Angiofibroma drugs are crucial for treating angiofibroma at a faster pace.
Data Bridge Market Research analyses a growth rate in the angiofibroma drugs market in the forecast period 2023-2030. The expected CAGR of angiofibroma drugs market is tend to be around 7% in the mentioned forecast period. The market was valued at USD 3 billion in 2022, and it would grow upto USD 5.15 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Angiofibroma Drugs Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Treatment (Excision, Dermabrasion, Beta Blockers Medication, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Galderma (Switzerland), Abbvie, Inc. (U.S.), Bausch Health Companies Inc. (Canada), Bristol Myers Squibb Company (U.S.) GSK Plc. (U.K), LEO Pharma A/S (Denmark), Novartis AG (Switzerland), Fresenius Kabi AG (Germany), Merck KGaA (Germany), Sanofi (France)
|
|
Market Opportunities
|
|
Market Definition
Angiofibroma is typically categorized as a group of lesions which includes fibrous papule, facial angiofibroma, adenoma sebaceum, periungual fibroma, pearly penile papule and Koenen's tumor. It is a benign vascular neoplasm nasal cavity tumour that is composed of dermal fibrous blood vessels. These diseases are usually diagnosed between the age group of 10 and 19 years old. It is normally caused by the local overgrowth of fibroblasts, collagen, and blood vessels. Therefore, the early diagnosis and treatment is the most vital step for the diseases prevention.
Global Angiofibroma Drugs Market Dynamics
Drivers
- Growing Cases of Angiofibroma
The increasing inicidence of angiofibroma results for around 0.05% of all head and neck tumors. A frequency of 1:5,000-1:60,000 in otolaryngology patients has been witnessed. Thus, this boosts the market growth.
- Huge Demand For Diagnostic Tests
The increasing demand of several diagnostic tests such as genetic screening, skin biopsy, histopathology tests are driving the growth of the market.
Opportunities
- Increasing Demand for Retail Pharmacies
Increase in the number of angiofibroma drugs being delivered through these retail pharmacies and rise in the number of retail pharmacies in highly developed countries create opportunities for the market growth. Furthermore, patients prefer retail pharmacies for purchasing drugs, as these are easily available.
Restraints/Challenges
- Side Effects of angiofibroma drugs
There are several side effects that are associated with angiofibroma drugs. Angiofibroma drugs can lead to itchiness and may also bleed. Those associated with genetic syndromes result in facial disfigurement and stigmatization.
- High Cost
The huge expenditure of the treatment methods hamper the market growth. Several treatment options such as excision, cryotherapy, topical rapamycin, beta blockers are not so cost-effective and thus hinder the growth of the market.
This angiofibroma drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the angiofibroma drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Angiofibroma Drugs Market Scope
The angiofibroma drugs market is segmented on the basis of treatment, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment
- Excision
- Dermabrasion
- Beta Blockers Medication
- Others
End-Users
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Angiofibroma Drugs Market Regional Analysis/Insights
The angiofibroma drugs market is analyzed and market size insights and trends are provided by treatment, distribution channel and end-user as referenced above.
The major countries covered in the angiofibroma drugs market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to have the highest market growth due to the presence of key manufacturers of the product is high and, increasing research and development activities, healthcare expenditure.
Asia-Pacific dominates the market due to increased new research and developments.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Angiofibroma Drugs Market Share Analysis
The angiofibroma drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to angiofibroma drugs market.
Key players operating in the angiofibroma drugs market include:
- Galderma (Switzerland)
- Abbvie, Inc. (U.S.)
- Bausch Health Companies Inc. (Canada )
- Bristol Myers Squibb Company (U.S.)
- GSK Plc. (U.K.)
- LEO Pharma A/S (Denmark)
- Novartis AG (Switzerland)
- Fresenius Kabi AG (Germany)
- Merck KGaA (Germany)
- Sanofi (France)
SKU-